COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: <a href="https://www.coronavirus.gov">https://www.coronavirus.gov</a>.

Get the latest research from NIH: <a href="https://www.nih.gov/coronavirus">https://www.nih.gov/coronavirus</a>.

COVID-19 is an emerging, rapidly evolving situation

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research from NIH: <u>https://www.nih.gov/coronavirus</u>.

**FULL TEXT LINKS** 



**Case Reports** 

> Oral Surg Oral Med Oral Pathol Oral Radiol, 113 (6), e25-9 Jun 2012

## Orofacial Granulomatosis Treated With Low-Level Laser Therapy: A Case Report

Elisabetta Merigo <sup>1</sup>, Carlo Fornaini, Maddalena Manfredi, Marco Meleti, Federico Alberici, Luigi Corcione, Carlo Buzio, Jean-Paul Rocca, Teore Ferri, Paolo Vescovi

**Affiliations** 

PMID: 22668714 DOI: 10.1016/j.0000.2011.12.005

## **Abstract**

**Objectives:** We report a case of orofacial granulomatosis successfully treated with low-level laser therapy (LLLT).

**Study design:** LLLT was delivered through a diode laser device (Lasemar Eufoton, Trieste, Italy) with the use of a 4-cm defocalized lens and power of 1 W. Treatment was administered in sessions of 5 irradiations of 1 minute each, with a 1-minute interval between 2 subsequent irradiations (power density 0.08 W/cm(2); fluence/application: 4.8 J/cm(2); fluence/session: 24 J/cm(2)). Laser therapy was repeated 12 times (3 times per week).

**Results:** After 2 weeks of LLLT applications, the patient reported an improvement of symptomatology as well as a decrease of labial swelling. Complete healing was observed after 1 month. The patient was followed for 2 years. No recurrence of swelling was observed during the follow-up.

**Conclusions:** Advantages of the LLLT approach include an absence of side effects, analgesic properties (usually reported after first application), and good patient compliance.

Copyright © 2012 Elsevier Inc. All rights reserved.

## LinkOut - more resources

**Full Text Sources** 

ClinicalKey

**Elsevier Science** 

Ovid Technologies, Inc.